February 16th  2005

14.30 -15.00 Opening Ceremony
A.M. Ballesta (Barcelona, Spain)

15.00 -17.00  Round Table.
NEW PERSPECTIVES ON TUMOR MARKERS
Chairmen: 
R. Lamerz (Munich, Germany)
S. von Kleist (Friburg, Germany)

Tumor markers in cancer of testes.
R. Lamerz (Munich, Germany) 

Follow-up of patients with carcinoid tumors: comparing Chromogranin A and 5’
Hydroxy-3-Indole Acetic Acid.   
H.M.G. Bonfrer , C.M. Korse, C.M. Taal. (Amsterdam, The Netherlands) 

The predictive value of preoperative elevated levels of CEA and CA 19.9 in colorectal cancer. Results of a multicenter study. 
A. van Dalen, A. Behbehani, A. Mathew, M. Farghaly, P. Stieber, D. Hofmann, D. Nagel, U. Lau-Werner,  L. Holubec, O. Topolcan, J. Finek, M. Cerna, V. Visokai, L. Lipska ( Gouda, The Netherlands)                 

20 years CA 19.9: from diagnosis to therapy in pancreatic cancer.
R. Klapdor ( Hamburg, Germany)

100% tumor specificity within the reference range.
P. Stieber (Munich, Germany)

17.00 -18.00
Meet the Expert in
TUMOR MARKERS IN UNKNOWN PRIMARY MALIGNANCIES.
P. Stieber (Munich, Germany),  R. Molina (Barcelona, Spain)

February 17th 2005

9.00 -11.00 SATELLITE SYMPOSIUM (Sponsorized by CAN AG DIAGNOSTICS).

NEW TOOLS FOR DETERMINATION OF SCCA IN SQUAMOUS CELL CANCER AND S-100 IN MALIGNANT MELANOMA
Chairmen:
R. Einarsson (Sweden), R. Molina (Barcelona, Spain)

New tools for establishment and characterization of monoclonal antibodies using phage display.
C. Fermer, O. Nilsson, E. Röijer (Gothenburg, Sweden).

Second generation squamous cell carcinoma antigen (SCCA) assays - technical and clinical performance
U. Dahlen, H.W.A. de Bruijn, C. Hall, O. Nilsson, R. Einarsson (Gothenburg, Sweden).

Different forms of squamous cell carcinoma antigen ( total SCCA, total SCCA1 and total SCCA2) in patients with benign and malignant diseases.
R. Molina, JM. Augé, X. Filella, A.M. Ballesta (Barcelona, Spain)

Different forms of squamous cell carcinoma antigen (total SCCA, total SCCA1 and total SCCA2) in lung cancer patients.
W. Kulpa, E. Wojcik, J. Kaminska, M. Kowalska, Z. Stasik, P. Dymek. (Cracow, Poland)

Serum S100 assays for prediction of survival and relapse during long-term follow up of malignant melanoma patients.
Å. Bolander, M. Bergqvist, D. Brattström, A. Larsson, R. Einarsson, G. Ullenhag,
P. Hesselius, G. Wagenius (Uppsala, Sweden).

11.00 -11.30 Coffee Break

11.30 -13.30 SATELLITE SYMPOSIUM (Sponsorized by ROCHE).
RECENT ADVANCES IN TUMOR MARKER TESTING.

Evaluation of a new method to determined S-100B: clinical applications alone and in combination with the melanoma inhibitory activity (MIA).
R. Molina, J.M. Auge, X. Filella, J. Domingo-Domenech, A.M. Ballesta. (Barcelona, Spain).

Use of PSA assay specific PSA and free PSA based artificial neuronal networks and different tumor markers for early detection of prostate cancer.
C. Stephan, M. Lein, K. Jung (Berlin, Germany)

Use of serum bone markers for early detection of bone metastases in prostate cancer patients.
C. Stephan, M. Lein, K. Jung (Berlin, Germany)

Proteomics.Looking for new biomarkers
G. Pestlin, M. Tacke, H. Bodenmueller, J.L. Hagmann, J. Karl, W. Zolg. (Munich, Germany)
 

15.30 -17.30 SATELLITE SYMPOSIUM (Sponsorized by BAYER).
NEW TUMOR MARKERS IN CÁNCER.

C-erbB-2/neu a good tumor marker in patients with breast cancer: Comparison with CEA and CA 15.3
R.Molina, J.M. Auge, X. Filella, A.M. Ballesta. (Barcelona, Spain)

Clinical value of serum HER-2/neu in managing breast cancer patients
R. Colomer (Girona, Spain)

Usefulness of cPSA in the detection of prostate cancer.
X. Filella, J Alcover*, R. Molina, D. Truan*, J.M. Augé, G. Casals, A.M. Ballesta. (Barcelona, Spain)

Introduction of complexed PSA in the clinical evaluation of the prostatic patient.
F.G. Veiga (La Coruña, Spain).

17.30 -19.00 Free Communications
Chairmen:
R. Marrades (Barcelona, Spain)
X. Filella (Barcelona, Spain)

17.30-17.50 O-1)  High concentrations of tumor markers: Knowledge from the experience
S.Crespi, M. Moragues, L.Garcia, J.Vilimelis, A.Mayol, A. Valls (Palma de Mallorca, Spain)

17.50-18.10 O-2) Prognostic factors in advanced NON SMALL CELL LUNG CANCER.
J. Trapé, J. Buxó, J. Pérez de Olaguer, M. Domenech , J. Franquesa (Manresa, Spain)

18.10- 18.30 O-3) Comparación con CEA, CA 125, SCC, CYFRA 21-1 y NSE. Evaluation of a new tumor marker, Pro-Gastrin-Releasing Peptide (ProGRP) in patients with lung pathologies: Comparison with CEA, CA 125, SCC, CYFRA 21-1 and NSE.
J.M. Augé, R. Molina, X. Filella, N. Viñolas, R. Marrades, J. Domingo, A.M. Ballesta (Barcelona, Spain)
 

February 18th 2005                      

8.45 -11.00  NEWS IN MOLECULAR BIOLOGY.
Chairman:
A. M. Ballesta (Barcelona, Spain)

 Micrometastases in sentinel lymph node biopsies in breast cancer, do they have clinical relevance?
M. Nap (Maastrich, The Netherlands)

Sentinel lymph node mapping and circulating tumor cells in breast cancer
D. Krag (Vermont, USA).

Genetic alterations in renal carcinoma
M. Maestro, M.T. Sanz-Casla, M. Vidaurreta ( Madrid, Spain)

Systems Pathology: A Novel Platform to the study of Human Cancer.
C. Cordón-Cardo ( New York, USA) 

Genetic and epigenetic alterations in gastrointestinal cancer.
M. Perucho (La Jolla, USA).

11.00 -11.30 Coffee Break

SATELLITE SYMPOSIUM (Sponsorized by ABBOTT  DIAGNOSTICS).

Abbott ARCHITECT: News on Tumor Markers.
Chairmen:
A.M. Ballesta (Barcelona, Spain), B. Dowell (Chicago, USA).

Squamous cell carcinoma antigen (SCC) in clinical practice
R. Molina, J.M. Augé, X. Filella, A.M. Ballesta (Barcelona, Spain).

Revisión de la Tecnología Architect. Architect Technology Overview
M. Schulten (Wiesbaden, Germany)

Multicenter evaluation of a chemoluminescent, microparticle-based assay for squamous cell carcinoma antigen on the ARCHITECT instrument system.
M. Blankestein, H. de Bruijn, H. MItchell, A. Dolci, M. Sandri, J. Olson. (Chicago, USA)

Optimized use of Total and Free prostate specific antigen (PSA).
U.K. Stenman (Helsinki, Finland).

15.30 - 17.30.  SATELLITE SYMPOSIUM (Sponsorized by DIA SORIN).
Chairwomen:
A. Ch. Aronsson

Clinical utility of cytokeratins as tumor markers. Review.
V. Barak (Jerusalem, Israel)

S-100B protein reporting in the same day of the clinical examination : a five years
experience.
R.M. Dorizzi, M. Governa, A. Tambuscio, P. Rizzotti, C. Monese, D. Barisoni  (Verona, Italy)

Clinical applications of protein S-100B as tumor marker in malignant melanoma.
L.O. Hansson (Stockholm, Sweden)

S. 100B as a predictor of brain metastases: Brain vs cerebrovascular damage
Mazzone P, M.A. Vogelbaum, T. Masaryk, T. Mekhail, V. Fazio, S. Mc Cartney,
N. Marchi, A. Kanner, D Janigro (Cleveland, USA).

S-100. Early detection of recurrence in malignant melanoma
J.M. Augé, R. Molina, X. Filella, J. Domingo-Domènech, T. Castel, C. Montagut,
S. Puig, R. Martí, M. Vera , J. Malvehy , P. Gascon,  B. Mellado. (Barcelona, Spain).
 

17.30 -18.30
Meet the Expert in UROLOGICAL CANCER.
Chairmen:
X. Filella, J. Alcober (Barcelona, Spain)

February 19th 2005

NEW GUIDELINES OF EGTM  (EUROPEAN GROUP ON TUMOR MARKERS).
Chairman:
R. Lamerz (Munich, Germany)

Clinical utility of biochemical markers in colorectal cancere: European Group on
tumor markers (EGTM) guidelines
J. Duffy, A. van Dalen, C. Haglund, L. Hansson, R. Klapdor, R. Lamerz, O. Nilsson,
C. Sturgeon, O. Topolcan. (Dublin, Ireland).

Breast cancer.
P. Stieber, (Munich, Germany)  R. Molina (Barcelona, Spain)

EGTM guidelines for prostatic cancer.
R. Lamerz, A. Semjonow, W. Albretch, V. Jarrige, S. Joniau, F. Junker, H. Schmidt,
H. van Poppel, P. Sibley, G. Soletörnos (Munich, Germany)

11.30-13.30  NEW TUMOR MARKERS

Chairmen:
A.M. Ballesta (Barcelona, Spain), G.C. Torre  (Pietra Ligure, Italy)

Speakers:

New Kallikrein markers for ovarian cancer
V. Barak, V. Sherman, V. Doviner, D. Edelman, E.P. Diamandis (Jerusalem, Israel).

Mammaglobin: A Breast-Specific Marker?
J. Duffy (Dublin, Ireland)

11.00-11.30. Coffee Break

Circulating tumor cells in breast cancer patients: Measurements and clinical utilty.
H. Fritsche. (Houston, USA)

Tissue inhibitor of metalloprotease-1 (TIMP1) in colorectal cancer.
J.H. Nielsen, I.J. Christensen, M.N. Loteen-Andersen, N. Brünner  (Denmark)
 

Comunicaciones a la mesa

O-4). IL-6: A new prognostic marker for bladder cancer
Y. Santos, A. Gutiérrez, A. Agud, X. Filella, R. Molina, A.M. Ballesta, D. Truan,
A. Franco , R. Álvarez-Vijande , C. Mallofré, A. Arch, E. García, L. Peri, R. Gutiérrez,
P. Luque, J. Alcover, A. Alcaraz. (Barcelona, Spain).

O-5) Valor pronóstico de la IL-18 en cáncer de vejiga. Prognostic values of IL-18 in bladder cancer
Y. Santos, A. Gutiérrez, A. Agud, X. Filella, R. Molina, A.M. Ballesta, David Truan,  R. Álvarez-Vijande, A. Franco, C. Mallofré, A. Arch, E. García, L. Peri, R. Gutiérrez,  P. Luque, J. Alcover, A. Alcaraz. (Barcelona, Spain)

13.30 -13.45 Closing Ceremony
 R. Molina (Barcelona, Spain)

POSTERS

P-1) Evaluation for detection SCC by two chemiluminescent microparticle
immunoassay.
J. García Redondo, M.C. Vázquez Cortizo. (Pontevedra, Spain)

P-2)  Evaluation for detection CA 15.3 by two chemiluminescent mircroparticle
immunoassay. 
J García Redondo, M.C. Vázquez Cortizo. (Pontevedra, Spain)

P-3) Evaluation for detection CA 125 by two chemiluminescent mircroparticle
immunoassay. 
J. García Redondo, M.C. Vázquez Cortizo (Pontevedra, Spain)

P-4) Technical and clinical performance of Beckman Coulter’s Acces^R BR Monitor ( CA 15.3 Antigen)  Immunoassay. 
V. Jarrige, K. Loveland, C. Carollo-Neumann, B. Parson, T. Smith, J. Todleben, I. Mizrahi. (San Diego, USA).

P-5) Technical and clinical performance of  Beckman Coulter’s Acces^R GI Monitor (CA 19.9 Antigen)  Immunoassay. 
V. Jarrige, P. Nunnelly, D. Arockiasamy, J. Dahl, T. Hanson, R. Parson, I. Mizrahi
(San Diego, USA).

P-6) Technical and clinical performance of Beckman Coulter’s Access^R OV Monitor
( CA 125 Antigen) Immunoassay.
V. Jarrige, I. MIzrahi, D. Ehresmann, J. Montgomery. (San Diego, USA).

P-7) Performance evaluation of the ARCHITECT^R CA 125II^TM Assay
T. Rosiere, M. Schlten, K. Peterson, T. Kettlety, H. Mayer, MA, Blankestein, M. Gion, A. Daunizeau, W. Roberts, R. Olson. (Chicago, USA)

P-8) Comparison of the performance of the ARCHITECT^R.CA 15.3TM Assay
J. Friese, M. Schulten, K. Peterson, T. Kettlety, H. Mayer, MA Blankestein, M. Gion, A. Daunizeau, W. Roberts, R. Olsen. (Chicago, USA).

P-9) The macroglobulin family proteins as universal tumor markers.
NA. Zorina, VN. Zorina, RM. Zorina (Novokuznetsk, Russia)

P-10) Cytokines serum levels changes at patients with metastatic cancer disease-pilot study.
O. Topolcan, L. Holubec, M. Karlikova, V. Treska, A. Sutnar,  S. Svodova, J. Finek (Prague, Chequia)

P-11) Comparative study of VEGF expresión in human tumours.
A. Aragón, A. Tejido Sánchez, C. Capitán Manjón, A. Calle Santiuste, A. Rosino,
I. Vega. (Madrid, Spain).

P-12)  Prognostic importante of TPS at colorectal carcinoma.
O. Topolcan, L. Holubec jr, V. Liska, S Svobodova, V. Treska, J. Finek,K. Ruppert, A. Sutnar. (Prague, Chequia)

P-13)  TPA Mono Total at Non Small Cell Lung Cancer
O. Topolcan, L. Holubec, V. Polivkova, M. Pesek, S. Svodova, J. Finek
(Prague, Chequia)

P-14)  Diagnostic value of CEA, CA 125, and AFP to differentiate between benign
and malignant pleural effusions.
L.M. Flores Solis, J.L. Hernández Domínguez, C. Palacios Martín. (Ourense, Spain).

P-15) Diagnostic value of CEA, CA 125, and AFP to differentiate between benign
and malignant ascites.
L.M. Flores Solís, JL. Hernández Domínguez, C. Palacios Martín. (Ourense, Spain).

P-16) Clinical significance of cytosolic cathepsin D in primary breast cancer
J.C. Rodríguez, L. García Bernardo, MT. Allende, MC. Roig, A. Álvarez, B. Fernández Llana, J. Vázquez, N. Zeidan, E. García Lucero, J. Rodríguez Sánchez, J.L. García-Muñiz, F. Vizoso. ( Oviedo, Spain).

P-17) Quantitative assessment of cytosolic concentration of HER-2/neu protein in
breast cancer by immunoenzymatic assay (ELISA). Clinical signification.
MT. Allende, L. García Bernardo, A. Rodil, A. Alvarez, E. García Lucero, J. Rodríguez Sánchez, JL. García Muñiz, B. Fernández Llana, F. Vizoso, N. Zeidan, C. Roig. (Oviedo, Spain).

P-18) Prognostic value of preoperative serum CA 15.3 levels in patients with primary breast cancer.
E. Garcia Lucero, A. Martin, MC. Roig, L. Garcia Bernardo, D. Corte, A. Alvarez, J. Rodríguez Sanchez, A. Roibas, B. Fernandez Llana, N. Zeidan, MT. Allende. (Oviedo, Spain).

P-19) Membranous levels of C-erbB-2 oncoprotein in gastric cancer. Relationship
with clinicopathological parameters.
M.D. Corte, A. Álvarez, M.T. Allende, L. García Bernardo, J. Sánchez Rodríguez, E. García Lucero, B. Fernández Llana, N. Zeidan, F. Vizoso, M.C. Roig, (Oviedo, Spain).

P-20) Predictive value of proliferating cell nuclear antigen and p53 protein the histopathologic response of preoperatively irradiated rectal carcinoma.
M. Galvan, M.J. Gaspar, M. Diez, O. Lozano, T. Ratia, F. Noguerales, J. Granell,
M.C. Coca. (Madrid, Spain).

P-21) Prevalence of BAT-26 microsatellite instability (MSI) identified by molecular análisis in patients suffering from colorectal cancer in the Basque Country.
A. Reta, I. Pericas. (San Sebastian, Spain).

P-22) Human Papilomavirus load in hybrid capture II: does increasing the cur-off
improve the accuracy of the test?.
J. Ordi, L.M. Puig-Tintoré, A. Torné, R. Esteve, M. Marginet, M. Santos, P. Jou, M. Solé, X. Iglesias, E. Campo. (Barcelona, Spain).

P-23) Semiotics and tumor markers
A.H. Kortsaris (Alexandroupolis , Greece)

P-24)  Effects of the antiestrogen treatment in bomarkers in patiens with breast cancer.
J. Trape, J. Buxo, J. Perez de Oleguer, A. Miguel, M. Doménech, J. Franquesa. (Manresa, Spain).

P-25) Minisequencing through multiplex primer extension analisis: simultaneous genotyping of CYP2C9*2.*3 and 5´lanking region (C1189T) plymorphsims in a caucasian population.
S. Mas, A. Crescenti, J.M. Vidal-Taboada, S. Borgoñon, F. Cuevillas, N. Laso, R. Molina, A.M. Ballesta, A. Lafuente (Barcelona, Spain).

P-26) Aberrant methylation of p16INK4a, p14ARF and hMLH1 in colorectal cancer. The influence of diet.
S. Mas, A. Crescenti, N. Laso, P. Gasso, R. Molina, A.M. Ballesta, A. Lafuente (Barcelona, Spain).

P-27) Serum COX2 mRNA’s detection: a methodological approach.
A. Martínez-Peinado, M.D. Herranz-Amo, J. de la Haba, C. Aguilera Gami (Cordoba, Spain).

Scientific Secretariat

Dr. Xavier Filella

Servicio de Bioquímica Clínica
Hospital Clínico Provincial
Villarroel, 170
08036 BARCELONA (Spain)

e-mail: xfilella@clinic.ub.es